- Home
- ACXP vs WWR Comparison
ACXP vs WWR Comparison
Compare ACXP & WWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- WWR
- Stock Information
- Founded
- ACXP 2017
- WWR 1977
- Country
- ACXP United States
- WWR United States
- Employees
- ACXP N/A
- WWR N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- WWR Metal Mining
- Sector
- ACXP Health Care
- WWR Basic Materials
- Exchange
- ACXP Nasdaq
- WWR Nasdaq
- Market Cap
- ACXP 8.4M
- WWR N/A
- IPO Year
- ACXP 2021
- WWR N/A
- Fundamental
- Price
- ACXP $0.47
- WWR $0.59
- Analyst Decision
- ACXP Strong Buy
- WWR Strong Buy
- Analyst Count
- ACXP 2
- WWR 1
- Target Price
- ACXP $10.00
- WWR $2.00
- AVG Volume (30 Days)
- ACXP 18.7M
- WWR 607.4K
- Earning Date
- ACXP 08-08-2025
- WWR 08-13-2025
- Dividend Yield
- ACXP N/A
- WWR N/A
- EPS Growth
- ACXP N/A
- WWR N/A
- EPS
- ACXP N/A
- WWR N/A
- Revenue
- ACXP N/A
- WWR N/A
- Revenue This Year
- ACXP N/A
- WWR N/A
- Revenue Next Year
- ACXP N/A
- WWR N/A
- P/E Ratio
- ACXP N/A
- WWR N/A
- Revenue Growth
- ACXP N/A
- WWR N/A
- 52 Week Low
- ACXP $0.30
- WWR $0.45
- 52 Week High
- ACXP $3.33
- WWR $1.32
- Technical
- Relative Strength Index (RSI)
- ACXP 52.38
- WWR 58.04
- Support Level
- ACXP $0.45
- WWR $0.59
- Resistance Level
- ACXP $0.59
- WWR $0.63
- Average True Range (ATR)
- ACXP 0.08
- WWR 0.03
- MACD
- ACXP -0.01
- WWR -0.00
- Stochastic Oscillator
- ACXP 27.06
- WWR 50.00
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.